Examining How Early Relapses Shape MS Disability Progression
26 September 2023
New study explores how relapses in early MS (ROMS) affect disability progression.
New study explores how relapses in early MS (ROMS) affect disability progression.
By Sharlene Brown, independent Board member and Chair of the National Advocacy Committee for MS Australia This feature piece
A new vaccine developed by Australian researchers is highly effective against Epstein-Barr virus (EBV) in laboratory models, strongly supporting ongoing development for use in humans.
New research shows that stem cell therapy was effective for patients with treatment-resistant, aggressive MS.
The MSBase Study Group has compared the effectiveness of three MS medications as alternative treatment options after discontinuation of natalizumab (Tysabri®).
Understanding MS is a free online course to improve your understanding and awareness of MS. More than 39,000 people from 170+ countries have enrolled in the course, with research showing it significantly improves MS-related knowledge, health literacy and confidence in communicating about MS.
MS Australia celebrates the successful outcome of the first round of Incubator Grants 2023, awarding four grants worth $92,565.
New research exploring cutting-edge Artificial Intelligence (AI) technology to better analyse MRI scans of patients with multiple sclerosis (MS) could unlock crucial insights into disease progression and pave the way for improved treatment of people living with the condition.
CEO Rohan Greenland highlights World Brain Day’s significance in promoting brain health and urges our politicians to take more action in supporting the one-in-six Australians affected by neurological and neuromuscular conditions.